Eli Lilly and Company (LLY) announced that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer who were randomized to receive a combination of ALIMTA with bevacizumab and carboplatin induction followed by ALIMTA plus bevacizumab maintenance-the ALIMTA arm-compared to the combination of paclitaxel with bevacizumab and carboplatin followed by bevacizumab maintenance-the paclitaxel arm.
The study did meet one of its secondary endpoints of improved progression-free survival for the ALIMTA arm. Eli Lilly said results will be presented on September 7 at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
For comments and feedback: editorial@rttnews.com